Lallemand Health Solutions is strengthening its strategic position in the microbiome field through contract development and manufacturing operations, with the launch of Expert’Biome (trademarked) CDMO by Lallemand.
With Expert'Biome, Lallemand Health Solutions aims to support partners in their development of next-generation strains by offering comprehensive services in the health industry. These services include strains research and development, bioprocesses scaling, drug manufacturing, and other production steps.
Jérôme Panes, President and General Manager at Lallemand Health Solutions, said: “Expert’Biome leverages 90 years of know-how, from research and development to pilot-scale production and commercial manufacturing for microorganisms, and uses cutting-edge technologies and innovative scientific approaches to pioneer next-generation strains.”
The microbiome is taking on new significance, as evidenced by increased research and development and commercial success
- Laurie Rey, Head of Expert'Biome Business Development
Panes continued: “Our manufacturing facilities adhere to the highest quality standards since several decades, including cGMP Pharma for investigational and commercial biological products, internationally recognised accreditations and licenses. We are committed to securing a leading position in this booming market.
“Laurie Rey, with a PhD in Molecular Biology, has been appointed as Head of Expert’Biome Business Development. She will bring her experience, cumulated in the last decade, in partnership development in the life sciences and biotechnology sectors. As the main point of contact for this activity, she will ensure streamlined project execution”.
Laurie Rey said: “The microbiome is taking on new significance, as evidenced by increased research and development and commercial success. Between 2021 and 2023, there has been a 24% increase in ongoing development trials worldwide, along with an 18% increase in countries with products in development targeting the microbiome. Over the past two years, several regulatory approvals have paved the way for next-generation microbiome strains as potential drugs to improve well-being in various health areas.”